Audio Journal of Oncology Podcast Wojciech Jurczak MD PhD; ASH 2025: Big Study Suggests Non-Covalent BTK Inhibitor Pirtobrutinib Could be New...
Jennifer A. Woyach MD, ASH 2024: The Non-Covalent Bruton’s Tyrosine Kinase-Inhibitor Pirtobrutinib is As Effective, While Less Toxic, In...
Audio Journal of Oncology Podcast New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia Play Episode Pause Episode Mute/Unmute...
Audio Journal of Hematology Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia? Play Episode Pause Episode Mute/Unmute Episode Rewind...
Audio Journal of Hematology Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia? Play Episode Pause Episode Mute/Unmute Episode Rewind...
NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic...